Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab in homozygous familial hypercholesterolemia
jRCT2080224038Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Evinacumab with Placebo (2 arms). Primary endpoint: Percent change from baseline in LDL cholesterol at week 24. Started Aug 2018; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on jRCT2080224038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224038.